1.Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents.
Ana Luiza Melo DOS SANTOS ; Helen DE MELO SANTOS ; Marina Bettiol NOGUEIRA ; Hugo Tadashi Oshiro TÁVORA ; Maria DE LOURDES JABORANDY PAIM DA CUN ; Renata Belém Pessoa DE MELO SEIXAS ; Luciana DE FREITAS VELLOSO MONTE ; Elisa DE CARVALHO
Pediatric Gastroenterology, Hepatology & Nutrition 2018;21(4):306-314
PURPOSE: The objective of this study was to describe the clinical phenotypes of children and adolescents with cystic fibrosis (CF); and to assess the role of pancreatic insufficiency and neonatal screening in diagnosis. METHODS: A cross-sectional study was conducted, which included 77 patients attending a reference center of CF between 2014 and 2016. Epidemiological data, anthropometric measurements, and the presence of pulmonary, pancreatic, gastrointestinal and hepatobiliary manifestations were evaluated based on clinical data and complementary examinations. RESULTS: Of the 77 patients, 51.9% were male, with a median age of 147 months (7.0-297.0 months), and the majority showed adequate nutritional status. The most common phenotype was pulmonary (92.2%), followed by pancreatic (87.0%), with pancreatic insufficiency in most cases. Gastrointestinal manifestation occurred in 46.8%, with constipation being the more common factor. Hepatobiliary disease occurred in 62.3% of patients. The group with pancreatic insufficiency was diagnosed earlier (5.0 months) when compared to the group with sufficiency (84.0 months) (p=0.01). The age of diagnosis was reduced following implementation of neonatal screening protocols for CF (6.0 months before vs. 3.0 months after, p=0.02). CONCLUSION: The pulmonary phenotype was the most common, although extrapulmonary manifestations were frequent and clinically relevant, and should mandate early detection and treatment. Neonatal screening for CF led to earlier diagnosis in patients with pancreatic failure, and therefore, should be adopted universally.
Adolescent*
;
Child*
;
Constipation
;
Cross-Sectional Studies
;
Cystic Fibrosis*
;
Diagnosis
;
Exocrine Pancreatic Insufficiency
;
Gastrointestinal Diseases
;
Humans
;
Infant, Newborn
;
Liver Diseases
;
Male
;
Neonatal Screening
;
Nutritional Status
;
Phenotype*
2.Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study).
Ubiratan Cardinalli ADLER ; Maristela Schiabel ADLER ; Ana Elisa Madureira PADULA ; Livia Mitchiguian HOTTA ; Amarilys DE TOLEDO CESAR ; José Nelson Martins DINIZ ; Helen DE FREITAS SANTOS ; Edson Zangiacomi MARTINEZ
Journal of Integrative Medicine 2022;20(3):221-229
BACKGROUND:
Different homeopathic approaches have been used as supportive care for coronavirus disease 2019 (COVID-19) cases, but none has been tested in a clinical trial.
OBJECTIVES:
To investigate the effectiveness and safety of the homeopathic medicine, Natrum muriaticum LM2, for mild cases of COVID-19.
DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS:
A randomized, double-blind, two-armed, parallel, single-center, placebo-controlled clinical trial was conducted from June 2020 to April 2021 in São-Carlos, Brazil. Participants aged > 18 years, with influenza-like symptoms and positive result from a real-time polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2 were recruited and randomized (1:1) into two groups that received different treatments during a period of at-home-isolation. One group received the homeopathic medicine Natrum muriaticum, prepared with the second degree of the fifty-millesimal dynamization (LM2; Natrum muriaticum LM2), while the other group received a placebo.
OUTCOME MEASURES:
The primary endpoint was time until recovery from COVID-19 influenza-like symptoms. Secondary measures included a survival analysis of the number and severity of COVID-19 symptoms (influenza-like symptoms plus anosmia and ageusia) from a symptom grading scale that was informed by the participant, hospital admissions, and adverse events. Kaplan-Meier curves were used to estimate time-to-event (survival) measures.
RESULTS:
Data from 86 participants were analyzed (homeopathy, n = 42; placebo, n = 44). There was no difference in time to recovery between two groups among participants who were reporting influenza-like symptoms at the beginning of monitoring (homeopathy, n = 41; placebo, n = 41; P = 0.56), nor in a sub-group that had at least 5 moderate to severe influenza-like symptoms at the beginning of monitoring (homeopathy, n = 15; placebo, n = 17; P = 0.06). Secondary outcomes indicated that a 50% reduction in symptom score was achieved significantly earlier in the homeopathy group (homeopathy, n = 24; placebo, n = 25; P = 0.04), among the participants with a basal symptom score ≥ 5. Moreover, values of restricted mean survival time indicated that patients receiving homeopathy might have improved 0.9 days faster during the first five days of follow-up (P = 0.022). Hospitalization rates were 2.4% in the homeopathy group and 6.8% in the placebo group (P = 0.62). Participants reported 3 adverse events in the homeopathy group and 6 in the placebo group.
CONCLUSION:
Results showed that Natrum muriaticum LM2 was safe to use for COVID-19, but there was no statistically significant difference in the primary endpoints of Natrum muriaticum LM2 and placebo for mild COVID-19 cases. Although some secondary measures do not support the null hypothesis, the wide confidence intervals suggest that further studies with larger sample sizes and more symptomatic participants are needed to test the effectiveness of homeopathic Natrum muriaticum LM2 for COVID-19.
TRIAL REGISTRATION
UMIN Clinical Trials Registry ID: JPRN-UMIN000040602.
COVID-19/therapy*
;
Double-Blind Method
;
Homeopathy
;
Humans
;
Influenza, Human/drug therapy*
;
Materia Medica/therapeutic use*
;
Primary Health Care
;
Treatment Outcome